Drug Profile
AZD 5438
Alternative Names: AZD5438Latest Information Update: 07 Aug 2006
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Solid tumours
Most Recent Events
- 20 Feb 2004 Phase-I clinical trials in Cancer in United Kingdom (unspecified route)
- 22 Jul 2003 Preclinical trials in Cancer in United Kingdom (unspecified route)
- 22 Jul 2003 Data presented at the 94th Annual Meeting of the American Association for Cancer Research (AACR-2003) have been added to the Cancer pharmacodynamics section